FDA Clinical HOld

Beam Therapeutics Shares Decline Following FDA's Clinical Hold On Leukemia Study

The U.S. Food and Drug Administration (FDA) has placed a clinical hold on Beam Therapeutics’ (NASDAQ: BEAM) Investigational New Drug (IND) application for the candidate BEAM-201 in the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL)/T cell lymphoblastic lymphoma (T-LL).

Sarepta Therapeutics' Shares Plummet Following FDA's Clinical Hold On MOMENTUM Study

The U.S. Food and Drug Administration (FDA) has placed a clinical hold on SRP-5051 (vesleteplirsen), Sarepta Therapeutics' (NASDAQ: SRPT) lead candidate to treat patients with Duchenne muscular dystrophy.